By Fineline Cube AbbVie (NYSE: ABBV) announced positive topline results from the Phase III CERVINO study evaluating etentamig, an investigational BCMA x CD3 bispecific T-cell engager, versus standard available therapies (SAT) in patients with triple-class exposed relapsed/refractory multiple myeloma (RRMM) — patients previously treated with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. The readout positions AbbVie’s second-generation bispecific as a potential new option in one of hematologic oncology’s most difficult-to-treat populations.
Study Overview
| Item | Detail |
|---|---|
| Sponsor | AbbVie (NYSE: ABBV) |
| Product | etentamig (investigational) |
| Study | CERVINO, Phase III |
| Design | Etentamig versus standard available therapies (SAT) |
| Population | Triple-class exposed relapsed/refractory multiple myeloma (proteasome inhibitor, immunomodulatory drug, anti-CD38 monoclonal antibody) |
| Result | Positive topline results |
| Date | 03 Sept 2026 |
Drug Profile & Mechanism of Action
- Molecule: etentamig, an investigational, second-generation BCMA x CD3 bispecific antibody T-cell engager
- Design Goal: Combine meaningful anti-myeloma activity with a differentiated treatment experience for patients
- Key Structural Features:
- Low-affinity CD3 binding domain — designed to reduce cytokine release syndrome (CRS) and infections
- High-avidity bivalent BCMA-binding domain — for potent target engagement on myeloma cells
- Retained FcRn binding — enabling monthly (Q4W) dosing after a single step-up dose
- Caution: Clinical correlations of these structure-activity relationships have not been fully established; the CERVINO data will be central to validating the design hypothesis
Clinical Evidence – CERVINO
- The CERVINO study produced positive topline results for etentamig versus standard available therapies in triple-class exposed RRMM patients
- The comparator arm reflects real-world practice, as patients who have progressed through the three dominant drug classes face limited and generally poor-performing remaining options
- Detailed efficacy and safety data from the study are expected to be presented at a future medical meeting
Market Impact & Outlook
- High-need segment: Triple-class exposed RRMM represents a rapidly growing population as patients survive longer through successive lines of therapy, with few effective options remaining
- Differentiation potential: If the engineered safety profile and monthly dosing are confirmed clinically, etentamig could offer a treatment experience advantage over first-generation bispecifics that require more frequent dosing and carry higher CRS risk
- Competitive landscape: The result strengthens AbbVie’s position in a crowded bispecific field targeting BCMA, where dosing convenience and tolerability are increasingly decisive commercial differentiators
- Portfolio momentum: The positive Phase III readout adds to AbbVie’s (NYSE: ABBV) expanding hematology-oncology pipeline beyond its legacy franchises
Forward‑Looking Statements: This brief is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Statements regarding clinical potential, regulatory submissions and market opportunity are forward-looking and subject to risks and uncertainties, including full data interpretation, regulatory decisions and competitive developments. Clinical correlations of etentamig’s structure-activity design have not been fully established. Actual results may differ materially. Readers should conduct their own due diligence before making investment decisions.-Fineline Info & Tech